EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›NVSEF

NVSEF

NOVARTIS AG

Next earnings Jul 21, 2026 · consensus $2.17 EPS, $14.5B rev

Sell
$153.38
▲ 0.00%
$153.38▲ +37.41%
over 1Y
L $107.99EODHDH $166.07
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+8.8%
1M+1.6%
3M-0.9%
YTD+11.7%
1Y+37.4%
OverviewValuationQualityFilings
Rating
Sell
Quality
—
Valuation
Fair value
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 34 analysts
Buy

Mixed signals in the latest filings.

NOVARTIS AG shows limited reported revenue.

Financials · annual, by fiscal year

No income data filed.

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$293B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-3.4%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
6-KPeriod ending 2026-06-112026-06-11open ↗144Filing2026-04-30open ↗6-KPeriod ending 2026-03-312026-04-28open ↗6-KPeriod ending 2026-03-182026-03-18open ↗424B5Filing2026-03-17open ↗FWPFiling2026-03-17open ↗424B5Filing2026-03-16open ↗144Filing2026-02-12open ↗144Filing2026-02-09open ↗S-8Filing2026-02-04open ↗6-KPeriod ending 2025-12-312026-02-04open ↗6-KPeriod ending 2025-12-312026-02-04open ↗

Quality score

—
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial health—
Momentum—
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals

Frequently asked

Is NOVARTIS AG (NVSEF) a buy?
NVSEF currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.

Sources: SEC EDGAR (CIK 0001114448, latest 6-K filed 2026-06-11) · EODHD · as of 6/20/2026, 7:19:19 AM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2020-07-14
NOVARTIS PHARMA AG
10% owner
Acquired (C)5.91M
2020-06-30
Novartis Bioventures Ltd
Insider
Acquired (C)856K
2020-06-30
Novartis Bioventures Ltd
Insider
Acquired (C)200K
2020-06-30
Novartis Bioventures Ltd
Insider
Buy125K @ $17.00$2.13M
2020-06-19
Novartis Bioventures Ltd
Insider
Sell1.00M @ $8.25$8.26M
2020-06-18
Novartis Bioventures Ltd
Insider
Sell900.00 @ $9.04$8.14K
2020-06-17
Novartis Bioventures Ltd
10% owner
Sell4.62K @ $9.27$42.8K
2020-06-16
Novartis Bioventures Ltd
10% owner
Sell8.60K @ $9.30$80.0K
2020-06-15
Novartis Bioventures Ltd
10% owner
Sell6.16K @ $9.05$55.8K
2020-06-12
Novartis Bioventures Ltd
10% owner
Sell1.50K @ $9.19$13.8K
2020-06-11
Novartis Bioventures Ltd
10% owner
Sell7.20K @ $9.21$66.3K
2020-06-10
Novartis Bioventures Ltd
10% owner
Sell8.53K @ $9.46$80.7K

Dividends

Annual
Yield (TTM)
3.1%
Annual / share
$4.77
Last ex-date
2026-03-11
Last amount
$4.77
ex 2026-03-11paid 2026-03-12$4.77
ex 2025-03-12paid 2025-03-13$3.85
ex 2024-03-07paid 2024-03-11$3.74
ex 2023-03-09paid 2023-03-13$3.22
ex 2022-03-08paid 2022-03-10$3.17
ex 2021-03-04paid 2021-03-08$3.09

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Recent news

market news →
Novartis (SWX:NOVN) Forms Antares Cancer Partnership And Expands Disability Access EffortsBullish
finance.yahoo.com· 2026-06-26
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?Bullish
finance.yahoo.com· 2026-06-26
The Zacks Analyst Blog Highlights Micron, MUU, MULL, SHOC,CHPX and FTXLBullish
finance.yahoo.com· 2026-06-26
The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCellBullish
finance.yahoo.com· 2026-06-26
Top Stock Reports for JPMorgan, Novartis & QualcommBullish
finance.yahoo.com· 2026-06-25
Candel Therapeutics Designates Mark Sims as CCOBullish
finance.yahoo.com· 2026-06-25

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score— vs 67
Revenue growth— vs 7.1%
Net margin— vs 10.5%
Return on equity— vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 39d
Bearish
-0.04
vs typical · 83 articles
↓ cooling

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.